Walk the independent claim. OPPO's grant US12310702B2, "Blood pressure measurement module, strap assembly, and wearable device" (issued May 27, 2025; inventor Shun Zhou), is a granted patent. Its CPC mix — A61B 5/02141 for blood-pressure measurement and A61B 5/681 for worn devices — marks a wrist blood-pressure claim.
The element that does the work is the strap integration. Wrist blood pressure is hard because reliable measurement traditionally needs an inflatable cuff and good arterial contact. The claim's contribution is building the measurement module into the strap assembly — using the band, which wraps the wrist, as the platform for the sensing, rather than confining it to the watch face.
What it reads on is a blood-pressure-capable smartwatch where the sensing lives in the band. Cuffless wrist blood pressure is one of the most sought-after and contested wearable-health features, and OPPO's appearance here marks a major Chinese device maker staking a claim in it.
Scope discipline: the claim protects the recited strap-integrated measurement module, not blood-pressure sensing generally and not watch-body-based approaches. A device that measures BP from the watch case, or via a materially different mechanism, may operate outside it. The defensible element is the in-strap module assembly.
Granted status places US12310702B2 in the dense, fiercely-contested wrist-blood-pressure space — where Samsung, Apple, and numerous specialists are all filing. The strap-integration angle is a distinct approach within that contest, and a competitor pursuing in-band BP sensing should map against it.
For a landscape analyst, the patent is a reminder that the wearable-health frontier is global and crowded. Cuffless wrist blood pressure is a frontier feature, and the assignees claiming it — OPPO among them — extend well beyond the usual American platform owners.